FDA-Labeled Indications for Chronic Weight Management As of early 2026, two medications carry FDA indications specifically for chronic weight management in adults: Wegovy (semaglutide 2.4 mg) approved 2021 Zepbound (tirzepatide) approved 2023 Liraglutide (Saxenda) is also approved for weight management but has been largely supplanted by the once-weekly options
Carrying groceries
Fourth, as we did not include a placebo group and compared with patients who were not using tirzepatide, there might be immortal time bias
In the thread, clinicians describe extreme constipation and bowel obstruction, sometimes with perforation and colostomy
Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial
To confirm its biological function, firstly we tried to measure the enzymatic activity of GpoA by comparison of total protein extracts obtained from wt and gpoA strains, but the reactivity of H 2 O 2 impeded to perform this enzymatic assay
